AstraZeneca is broadening its role in oncology and autoimmune disease with advances in immuno-oncology, gastrointestinal and ...

AstraZeneca has reported positive results from the efzimfotase alfa Phase III clinical trial programme for hypophosphatasia ...

The systemic lupus erythematosus (SLE) market continues to evolve toward biologic-driven care, with increasing treatment complexity, intensifying competition among advanced therapies, and a robust ...

Prior to this, AstraZeneca reported positive results from the efzimfotase alfa Phase III clinical trial programme for ...

April 2 () - AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Astrazeneca (AZN) is a stock that can certainly grab the attention of many investors ...

Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the ...

After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...

Extortion: Notorious hackers offering to sell 3GB of data containing highly sensitive intellectual property & infrastructure configuration details.

AstraZeneca Plc AZN released topline data from the Phase 3 program for efzimfotase alfa (ALXN1850) in the broad hypophosphatasia (HPP) patient population. HPP is a rare, inherited metabolic disorder ...

A potential treatment developed by AstraZeneca for hypophosphatasia has showed positive results in phase III trials, the ...

Transparency is a word pharma companies often like to use, but, in practice, they rarely live up to the ideal. AstraZeneca is trying to be truly transparent with its new Discovery Centre (DISC). The ...